Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US

Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US

Shots:

  • Therapeutics MD to receive $15.82M upfront, $33.34M milestones including $2.26M as regulatory milestones & $31.08M as commercial milestones and royalties on sales in licensed territories
  • Theramex to get exclusive commercialization rights for Bijuva and Imvexxy outside the US and is responsible for all regulatory and commercial activities in the licensed territories. Additionally, Therapeutics MD has licensed Bijuva and Imvexxy to Knight Therapeutics in Canada & Israel
  • Bijuva is a bio-identical hormone therapy combination of estrogen and progesterone indicated for moderate to severe vasomotor symptoms. IMVEXXY is a vaginal estrogen therapy indicated to treat painful sexual activity

Click here to read full press release/ article | Ref: Therapeutics MD| Image: Theramex